Search for: [Abstract = "Methods We included consecutive patients with severe symptomatic AS whounder went standalone BAV, BAV with coronary angiography\/PCIand\/or TAVI. All patients were qualified for invasive treatment by an interdisciplinary team of specialists \(heart team\). The procedural risk was estimated by the logistic European System for Cardiac Operative Risk Evaluation II \(EuroSCORE II\) and the Society of Thoracic Surgeons Predicted Risk of Mortality \(STS\) score. The study was approved by the local ethical committee. Clinical and echocardiographic data were prospectively collected within 1, 6, and12 months follow\-up after BAV or until received TAVI\/AVR, re\-BAVor death. Procedure Coronary angiography\/PCI was guided by fluoroscopy. The same femoral retrograde approach was used in case of concomitant coronary angiography\/PCI and then during BAV to reach in aortic valve under echocardiographic and fluoroscopic guidance. Vascular accesses wereclosed with Angio\-Seal vascular closure device \(St. Jude Medical,USA\) or with manual compression. Baseline and procedural characteristics, as well as long\-term outcomes were assessed in three groups \- stand alone BAV, BAV with coronary angiography \(only\),and BAV combined with PCI. In case of TAVI after valve deployment angiography, echocardiography, and the aortic regurgitation index\(ARI\) were used to assess the severity of PVL before and after balloonPD. Patients were divided into two groups based whether or not PDafter TAVI was performed. Reduction of PVL, change of ARI, andclinical outcomes was assessed."]

Number of results: 0